Powered by the obesity gold rush and led by Eli Lilly's record-breaking tirzepatide, Evaluate's 2026 World Preview shows that pharma is set to break the new sales barriers in the coming years.
Powered by the obesity gold rush and led by Eli Lilly's record-breaking tirzepatide, Evaluate's 2026 World Preview shows that pharma is set to break the new sales barriers in the coming years.